Inovio Pharmaceuticals
105 hedge funds and large institutions have $192M invested in Inovio Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 54 increasing their positions, 15 reducing their positions, and 9 closing their positions.
260% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 15
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
26% more capital invested
Capital invested by funds: $153M → $192M (+$39.1M)
7% more funds holding
Funds holding: 98 → 105 (+7)
0.67% more ownership
Funds ownership: 2.59% → 3.26% (+0.67%)
42% less call options, than puts
Call options by funds: $1.83M | Put options by funds: $3.16M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
INO Hedge Fund Activity: Q2 2015 in Review
105 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2015, worth a combined $192M — up 26% from $153M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new INO positions and 9 closed out — a net gain of 7 holders — while 54 added to existing stakes and 15 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $8.57M. The largest seller was Putnam Investments, cutting an estimated $5.26M.
- 105 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2015, up from 98 in Q1 2015.
- Funds reported $192M of Inovio Pharmaceuticals stock for Q2 2015, up 26% quarter-over-quarter.
- 16 funds opened new Inovio Pharmaceuticals positions in Q2 2015 and 9 closed out, a net change of +7 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2015 was Susquehanna International Group, an estimated $8.57M added.
- The largest Inovio Pharmaceuticals seller in Q2 2015 was Putnam Investments, an estimated $5.26M sold.
Based on aggregated 13F filings for Q2 2015.